InsiderSignal.AI

InsiderSignal.ai

GILD - Gilead Sciences, Inc.

Insider Sale by Mercier Johanna (Chief Comm, Corp Aff Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Mercier Johanna, serving as Chief Comm, Corp Aff Officer at Gilead Sciences, Inc. (GILD), sold 3,000 shares at $140.96 per share, for a total transaction value of $422,880.00. Following this transaction, Mercier Johanna now holds 128,779 shares of GILD.

This sale represents a 2.00% decrease in Mercier Johanna's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 15, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 16, 2026, 1 day after the trade was made.

Gilead Sciences, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - GENERAL industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Mercier Johanna

Chief Comm, Corp Aff Officer

Johanna Mercier is the Chief Commercial & Corporate Affairs Officer at Gilead Sciences, Inc. (GILD), where she drives top-line revenue growth, expands access to therapies in virology, oncology, and inflammation, and oversees public and government affairs worldwide.[[1]](https://www.gilead.com/company/leadership/johanna-mercier)[[5]](https://www.gilead.com/company/leadership) She joined Gilead in 2019 after 25 years at Bristol Myers Squibb in senior leadership roles across U.S. and international markets.[[1]](https://www.gilead.com/company/leadership/johanna-mercier)[[2]](https://schaeffer.usc.edu/people/johanna-mercier/) Mercier has led key initiatives, including the rapid global launch of Gilead’s COVID-19 antiviral Veklury (remdesivir) during the pandemic with product donations, and the historic launch of lenacapavir, a long-acting HIV prevention option, achieving first shipments to low- and middle-income countries within five months of U.S. approval.[[1]](https://www.gilead.com/company/leadership/johanna-mercier)[[2]](https://schaeffer.usc.edu/people/johanna-mercier/) She serves on the boards of Arcus Biosciences, Neurocrine Biosciences, and the University of Southern California’s Leonard D. Schaeffer Center for Health Policy and Economics, and holds a bachelor’s degree in biology from the University of Montreal and an MBA from Concordia University.[[1]](https://www.gilead.com/company/leadership/johanna-mercier)[[2]](https://schaeffer.usc.edu/people/johanna-mercier/) Recently, as a corporate insider, she disposed of GILD common shares.[[3]](https://www.itiger.com/news/2612737422)

View full insider profile →

Trade Price

$140.96

Quantity

3,000

Total Value

$422,880.00

Shares Owned

128,779

Trade Date

Wednesday, April 15, 2026

2 days ago

SEC Filing Date

Thursday, April 16, 2026

Filed 1 day after trade

HEALTHCAREDRUG MANUFACTURERS - GENERAL

About Gilead Sciences, Inc.

Company Overview

No company information available
View news mentioning GILD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5696846

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime